113 related articles for article (PubMed ID: 6293981)
1. Release of eosinophil chemotactic leukotriene from neutrophils of patients with pseudo-allergic reactions.
Czarnetzki BM
Int Arch Allergy Appl Immunol; 1983; 70(1):78-82. PubMed ID: 6293981
[TBL] [Abstract][Full Text] [Related]
2. Release of neutrophil and eosinophil chemotactic factor from sensitized skin in vitro cutaneous anaphylactic reactions.
Numata T; Kimura K; Tsuboi K; Yamada S; Yamamoto S
Dermatologica; 1989; 179 Suppl 1():119. PubMed ID: 2550284
[No Abstract] [Full Text] [Related]
3. Effect of platelet activating factor on leukocytes. II. Enhancement of eosinophil chemotactic factor and beta-glucuronidase release.
Czarneztki BM
Chem Phys Lipids; 1982 Oct; 31(2):205-11. PubMed ID: 6814773
[TBL] [Abstract][Full Text] [Related]
4. Effects of novel lipoxygenase products on migration of eosinophils and neutrophils in vitro.
Udén AM; Palmblad J; Lindgren JA; Malmsten C
Int Arch Allergy Appl Immunol; 1983; 72(1):91-3. PubMed ID: 6307891
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of shale oils (Ichthyols) on the secretion of chemotactic leukotrienes from human leukocytes and on leukocyte migration.
Czarnetzki BM
J Invest Dermatol; 1986 Dec; 87(6):694-7. PubMed ID: 2878051
[TBL] [Abstract][Full Text] [Related]
6. Secretion of a chemotactic factor for neutrophils and eosinophils by alveolar macrophages from asthmatic patients.
Gosset P; Tonnel AB; Joseph M; Prin L; Mallart A; Charon J; Capron A
J Allergy Clin Immunol; 1984 Dec; 74(6):827-34. PubMed ID: 6334110
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the eosinophil chemotactic factor (ECF) release from human PMNs and rat mast cells by arachidonic acid analogs.
Kroegel C; Kunau HW; König W
Cell Immunol; 1981 May; 60(2):480-8. PubMed ID: 7237570
[No Abstract] [Full Text] [Related]
8. Generation of leukotrienes and lipoxygenase factors from human polymorphonuclear granulocytes during bacterial phagocytosis and interaction with bacterial exotoxins.
Bremm KD; Brom J; König W; Spur B; Crea A; Bhakdi S; Lutz F; Fehrenbach FJ
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 Jul; 254(4):500-14. PubMed ID: 6326424
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel and highly potent eosinophil chemotactic lipid in human eosinophils treated with arachidonic acid.
Morita E; Schröder JM; Christophers E
J Immunol; 1990 Mar; 144(5):1893-900. PubMed ID: 2155268
[TBL] [Abstract][Full Text] [Related]
10. Leukotrienes and lipoxygenase factors: mediators and modulators of the allergic reaction.
Konig W; Bohn A; Bremm KD; Müller P; Szperalski B; Pfeiffer P
Allergol Immunopathol (Madr); 1982; 10(5):385-94. PubMed ID: 6187199
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil and eosinophil chemotactic factors released from human keratinocytic (hair follicular) tumor cells.
Kanzaki T
Dermatologica; 1989; 179 Suppl 1():118. PubMed ID: 2476337
[No Abstract] [Full Text] [Related]
12. Comparison of the eosinophil chemotactic factor (ECF) with endogeneous hydroxyeicosatetraenoic acids of leukocytes.
König W; Kroegel C; Kunau HW; Borgeat P
Int Arch Allergy Appl Immunol; 1981; 66 Suppl 1():168-71. PubMed ID: 6273325
[No Abstract] [Full Text] [Related]
13. Biological and chemical characterization of eosinophil chemotactic factors from human leukocytes.
Czarnetzki BM; Grabbe J
Agents Actions Suppl; 1983; 12():204-16. PubMed ID: 6573116
[No Abstract] [Full Text] [Related]
14. From eosinophil chemotactic factor of anaphylaxis to leukotriene B4--chemistry, biology and functional significance of eosinophil chemotactic leukotrienes in dermatology.
Czarnetzki BM; Rosenbach T
Dermatologica; 1989; 179 Suppl 1():54-9. PubMed ID: 2550288
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the eosinophil chemotactic factor (ECF) release from various cells and their subcellular components by phospholipids.
König W; Kroegel C; Pfeiffer P; Tesch H
Int Arch Allergy Appl Immunol; 1981; 65(4):417-31. PubMed ID: 6788714
[TBL] [Abstract][Full Text] [Related]
16. Identification of 5-oxo-15-hydroxy-6,8,11,13-eicosatetraenoic acid as a novel and potent human eosinophil chemotactic eicosanoid.
Schwenk U; Morita E; Engel R; Schröder JM
J Biol Chem; 1992 Jun; 267(18):12482-8. PubMed ID: 1618754
[TBL] [Abstract][Full Text] [Related]
17. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
Carty TJ; Sweeney FJ; Griffiths RJ; Eskra JD; Ernest MJ; Pillar JS; Cheng JD; Loose LD; Joseph PA; Pazoles PP; Moore PF; Nagahisa A; Murase S; Kadin SB
Inflamm Res; 1997 May; 46(5):168-79. PubMed ID: 9197987
[TBL] [Abstract][Full Text] [Related]
18. Leukotriene B4 and neutrophil-derived eosinophil chemotactic factor: comparison of their biological activities.
Czarnetzki BM; Frosch PJ; Mardin M; Macher E
Monogr Allergy; 1983; 18():193-5. PubMed ID: 6316127
[No Abstract] [Full Text] [Related]
19. [Generation of eosinophil chemotactic factor of anaphylaxis in patients with cold urticaria and study of its in vitro chemotactic deactivation].
Ibáñez MD; Leyva Cobián F; Díaz Gómez ML
Med Clin (Barc); 1986 May; 86(19):794-7. PubMed ID: 3736185
[No Abstract] [Full Text] [Related]
20. Generation of leukotrienes from normal epidermis and their demonstration in cutaneous disease.
Rosenbach T; Grabbe J; Möller A; Schwanitz HJ; Czarnetzki BM
Br J Dermatol; 1985 Jul; 113 Suppl 28():157-67. PubMed ID: 2990517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
